IPOX® Analyst Muehlbauer provides expert analysis in Bloomberg on current European IPO trends and why investors are becoming more discerning. He emphasized the growing importance of strong company fundamentals amidst the heightened market volatility.

IPOX® Research Analyst Lukas Muehlbauer was recently quoted by Reuters regarding the impact of market instability on IPOs, specifically commenting on reports that Swedish fintech Klarna has paused its plans for a U.S. listing.

IPOX® Research Analyst Dr. Lukas Muehlbauer was recently interviewed by Reuters about Nvidia-backed CoreWeave's downsized IPO. "The business model doesn't appear fundamentally flawed, but this suggests investors are recalibrating AI infrastructure valuations," noted Muehlbauer as CoreWeave reduced its offering to 37.5 million shares at $40 each, valuing the company at approximately $23 billion—significantly below initial expectations.

IPOX® CEO Josef Schuster was recently interviewed by Reuters regarding eToro's US IPO filing. Schuster noted that companies are seeing a "window of opportunity" to go public and highlighted how eToro's IPO positions the platform to "capture the generational opportunities opening up from the rise of the retail investor globally."

IPOX® CEO Josef Schuster was recently quoted by Reuters on StubHub's IPO filing. The ticketing giant's move to list on the NYSE under "STUB" signals growing confidence in the recovering U.S. IPO market, with Schuster noting it "remains one of the most closely watched IPOs this year and ahead of FIFA 2026."

IPOX® CEO Josef Schuster was recently interviewed by the Financial Times regarding Venture Global's troubling market performance. Following a 36% single-day stock plunge, Schuster provided expert analysis on the LNG producer's IPO struggles.

IPOX® CEO Josef Schuster was interviewed by Bloomberg to discuss Venture Global's aftermarket performance following its recent IPO. Schuster provided insights into the challenging market conditions faced by Venture Global, emphasizing its notably poor stock performance compared to other major energy IPOs in recent decades.

IPOX® CEO Josef Schuster commented in a recent Reuters article, "Karman Holdings valued at nearly $4 billion as shares jump in NYSE debut", offering expert analysis on Karman Holdings' successful IPO and the broader market trends favoring defense and space companies.

IPOX® CEO Josef Schuster was quoted in a recent Reuters article, "Cybersecurity firm SailPoint sets sights on $12.6 billion valuation in US IPO", providing expert insight into SailPoint's IPO and the broader implications for the technology IPO market.

IPOX® Research Analyst Lukas Muehlbauer offered his perspective on the market debut of Maze Therapeutics (MAZE.O), a drug developer focused on chronic kidney diseases. Maze's shares saw a modest 1% increase on its Nasdaq debut, valuing the company at $690.37 million. The company’s debut follows an upsized IPO that raised $140 million.

IPOX® Research Analyst Lukas Muehlbauer offered his expert perspective on the market debut of Metsera, a GLP-1 weight-loss drug developer that achieved a $2.7 billion valuation following a 42% surge in its Nasdaq IPO. Metsera's strong performance underscores the robust investor appetite within the innovative obesity therapeutics sector.

IPOX® CEO Josef Schuster told Reuters that Venture Global's IPO "low float" presents a "significant risk," underscoring a challenging environment for energy IPOs to achieve high premiums and highlighting the importance of float considerations in new listings.

IPOX® CEO Josef Schuster told Bloomberg that Venture Global's IPO valuation cut "jolts" the market, signaling a crucial shift: investors now demand realistic valuations and rigorous IPO deal scrutiny, emphasizing increased investor discipline as the new norm.

IPOX® Research Analyst Dr. Lukas Muehlbauer, offered his perspective on the upcoming US IPO of Ascentage Pharma, a Chinese biopharmaceutical firm targeting a valuation of $1.75 billion. Ascentage, backed by Takeda Pharmaceutical, is seeking a US listing after its shares have already been trading on the Hong Kong stock exchange since 2019.

IPOX® CEO Josef Schuster shared his insights on the upcoming IPO of Smithfield Foods, which aims for a valuation of up to $10.73 billion. The pork producer's return to the U.S. stock market after over a decade is one of the first major consumer IPOs of the year, potentially setting a precedent for other companies in the sector.

IPOX® CEO Josef Schuster spoke with Bloomberg about the expected rebound in US energy IPOs, driven by companies like Venture Global. Schuster noted rising commodity prices and recent IPO successes create a favorable environment, adding that the market is "ready for a slew of good energy IPOs."

IPOX® CEO Josef Schuster sat down with Chuck Jaffe on the Money Life with Chuck Jaffe podcast to discuss the state of the IPO market, its strong performance amid market highs, and the factors driving its momentum. Schuster highlighted the role of low interest rates, robust earnings, and the rise of sectors like AI and industrials in fueling IPO growth.

Josef Schuster, founder and CEO of IPOX Schuster LLC, was recently featured in Reuters, offering his perspective on the upcoming IPO of ServiceTitan, which aims for a valuation of up to $5.16 billion.

IPOX® CEO Josef Schuster shared insights with Bloomberg on the renewed optimism in Canada’s IPO market, highlighted by Groupe Dynamite Inc.’s C$300 million debut. Schuster emphasized the IPOX® Canada Opportunities Index's adaptability, which has delivered a strong 36% return this year, outperforming the S&P/TSX Composite Index. The index reflects growing investor confidence and emerging opportunities as Canada’s equity markets show signs of recovery.

IPOX® CEO Josef Schuster, portfolio manager and subadvisor to the Rakuten Global IPO Stock Fund, was featured in Japan’s Nikkei Newspaper (日本経済新聞), talking about Reddit’s impressive post-IPO growth, underscoring IPOX's focus on identifying high-potential companies in the evolving global IPO landscape.